12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Bionomics (NASDAQ:BNOX) stock moved upwards by 38.9% to $3.75 during Monday’s regular session. The current volume of…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Femasys (NASDAQ:FEMY) shares moved upwards by 56.8% to $0.52 during Monday’s after-market session. This security traded at…
U.S. Food And Drug Administration Approves Orphan Drug Designation For Immix Biopharma NXC-201 As A Treatment For Amyloid Light Chain Amyloidosis
FDA Orphan Drug Designation ("ODD") qualifies one-time treatment NXC-201 for:
7 years of U.S. market exclusivity after approval
Tax credits for qualified clinical testing
Waiver of the Prescription Drug
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site
Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.Plan for NXC-201 to expand into earlier lines of therapy, and beyond the 5% of U.S. hospitals that
U.S. Food and Drug Administration Approves Orphan Drug Designation For Immix Biopharma NXC-201 As A Treatment For Multiple Myeloma
FDA Orphan Drug Designation ("ODD") qualifies NXC-201 for:
7 years of U.S. market exclusivity after approval
Tax credits for qualified clinical testing
Waiver of the Prescription Drug User Fee (currently
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) stock rose 33.3% to $41.0 during Tuesday’s after-market session. Apellis Pharmaceuticals’s trading volume hit…
Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted For Oral Presentation At The 20th International Myeloma Society Annual Meeting September 27-30 In Athens Greece
Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today
Immix Biopharma Reports 2nd Interim Clinical Trial Data Readout In Relapsed/Refractory Metastatic Colorectal Cancer In Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal
Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. ("Nexcella", "Company", "We" or "Us"), today announced the completion of its initial CAR-T NXC-201 engineering batch at its
12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers Castle Biosciences (NASDAQ:CSTL) shares rose 54.4% to $20.5 during Friday’s regular session. Trading volume for this security…